TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ACRS

Aclaris Therapeutics Inc

Healthcare · Biotechnology

5.40$ +1.5% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement ACRS
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
71.7% 67.9% 95.9% 79.2% 69.7% 40.2% 57.9% 14.9% 26.7%
28.3% 32.1% 4.1% 20.8% 30.3% 59.8% 42.1% 85.1% 73.3%
2,364.2% 624.4% 1,535.3% 489.5% 648.0% 261.5% 314.8% 179.4% 672.7%
1,967.3% 274.0% 642.4% 316.7% 349.3% 84.5% 99.5% 118.6% 280.8%
4,331.5% 1,374.0% 2,193.7% 806.2% 1,357.4% 361.8% 353.7% 843.3% 1,049.2%
-4,303.2% -1,341.9% -2,627.3% -785.4% -1,327.1% -302.0% -311.6% -758.2% -975.9%
0.0% 0.0% 0.0% 16.0% 346.3% 15.8%
-4,180.2% -1,315.4% -2,686.1% -792.0% -1,344.0% -292.1% -284.3% -705.5% -829.6%
-108.7% 26.5% 693.4% -2.8% 346.3% 5.9% -1.2%
-4,071.5% -1,315.4% -3,817.2% -789.2% -1,344.0% -292.1% -283.1% -705.5% -829.6%
-4,279.3% -1,323.3% -2,134.7% -765.0% -953.4% -283.5% -369.5% -276.3% -823.8%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?